GSK (GSK) announced that new data across the oncology pipeline and portfolio will be presented in more than 60 abstracts at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL and the 30th European Hematology Association, EHA, Congress in Milan, Italy. These results highlight GSK’s research and development programs which aim to improve outcomes for patients with blood cancers, gynecologic cancers and other solid tumors through innovative therapeutic approaches. The showcased data includes: Latest data on Blenrep combinations underscore the potential to transform treatment of 2L+ multiple myeloma; New analyses from MOMENTUM and SIMPLIFY-1 trials at EHA emphasise importance of early intervention with Omjjara; New data across phase III studies at ASCO show the impact of Jemperli and Zejula in advanced gynaecologic cancers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data
- Scynexis resumes patient dosing in Phase 3 MARIO study
- GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy
- Spero Therapeutics, GSK announce Phase 3 PIVOT-PO trial met primary endpoint
- AnaptysBio price target raised to $90 from $54 at Guggenheim